How a radioactive cancer treatment works in real-world prostate cancer care

This is a real-world study that follows men with advanced prostate cancer who are being treated with lutetium (177Lu) vipivotide tetraxetan, a radioactive medication designed to target cancer cells. Researchers will track how the medication works, its side effects, and how it affects daily life by collecting information from medical records and patient reports. The study has two groups: men whose cancer has become resistant to hormone therapy, and men with newly diagnosed advanced prostate cancer.

While this medication has shown promise in clinical trials, researchers want to understand how it performs in real-world settings outside of controlled research environments, and which patients benefit most from this treatment.